CN113005149A - 一种表达冠状病毒受体结合域串联二聚体的重组副流感病毒5型载体 - Google Patents

一种表达冠状病毒受体结合域串联二聚体的重组副流感病毒5型载体 Download PDF

Info

Publication number
CN113005149A
CN113005149A CN202110327109.6A CN202110327109A CN113005149A CN 113005149 A CN113005149 A CN 113005149A CN 202110327109 A CN202110327109 A CN 202110327109A CN 113005149 A CN113005149 A CN 113005149A
Authority
CN
China
Prior art keywords
leu
ser
ile
thr
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110327109.6A
Other languages
English (en)
Inventor
刘金华
孙洪磊
孙浩然
李涵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
China Agricultural University
Original Assignee
China Agricultural University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by China Agricultural University filed Critical China Agricultural University
Priority to CN202110327109.6A priority Critical patent/CN113005149A/zh
Publication of CN113005149A publication Critical patent/CN113005149A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18711Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18741Use of virus, viral particle or viral elements as a vector
    • C12N2760/18743Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/20011Coronaviridae
    • C12N2770/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/20011Coronaviridae
    • C12N2770/20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

本发明公开一种表达冠状病毒Spike蛋白的受体结合域串联二聚体的重组副流感病毒5型载体,所述重组副流感病毒5型载体包含一种副流感病毒5型基因组,所述副流感病毒5型基因组包含冠状病毒Spike蛋白的受体结合域串联二聚体的基因序列。实验证明rPIV5‑tr‑RBD对2019‑nCoV冠状病毒具有优良的免疫保护效果。本发明具有重要的应用价值。

Description

一种表达冠状病毒受体结合域串联二聚体的重组副流感病毒 5型载体
技术领域
本发明涉及生物技术领域,具体涉及一种表达冠状病毒受体结合域串联二聚体的重组副流感病毒5型载体。
背景技术
新冠肺炎的临床症状包括发热、干咳、乏力等,患者可出现鼻塞、流涕、咽痛、结膜炎等多种症状,重症患者可出现呼吸困难、低氧血症,严重者可发展为急性呼吸窘迫综合征、脓毒症休克等甚至导致死亡。
疫苗接种是预防新冠病毒的最有效手段之一,目前各国已有多个研究机构进行新冠疫苗的制备,包括灭活疫苗,重组蛋白疫苗,重组腺病毒疫苗,mRNA疫苗以及病毒载体疫苗等。灭活疫苗可以有效地激发高水平的体液免疫,相对安全,但不能诱导细胞毒T淋巴细胞反应,不能够产生局部免疫反应;重组蛋白疫苗技术成熟,不良反应小,但生产速度较慢;重组腺病毒疫苗虽然免疫效果好,但可能会存在一定的不良反应,且人体内可能含有针对腺病毒载体的抗体,会影响疫苗效果;mRNA疫苗相对效果好,但存储运输条件相对较为苛刻,成本较高。
病毒载体疫苗具有多种优势,由于是活病毒载体,可在免疫动物体内进行复制,诱导较强的免疫反应;可通过自然感染,如滴鼻、喷雾等方式进行免疫;可产生体液免疫与细胞免疫,除了激发全身免疫反应外,还可激发局部免疫反应,如在呼吸道中产生sIgA抗体,发挥较强的免疫保护效果。目前,在新冠疫苗的研发过程中,已有多种病毒载体疫苗在研发过程中,并在动物模型中具有良好的免疫保护效果,如黄热病毒、痘病毒、新城疫病毒、水疱口炎病毒等。副流感病毒5型(PIV5)作为预防犬窝咳的疫苗在犬中应用已有数十年的历史,而且未被证实可引起任何其他动物包括人致病。
发明内容
本发明提供一种表达冠状病毒Spike蛋白的受体结合域串联二聚体(Tandemrepeat Receptor-binding domain,tr-RBD)的重组副流感病毒5型载体,
所述重组副流感病毒5型载体包含一种副流感病毒5型基因组,所述副流感病毒5型基因组包含冠状病毒Spike蛋白的受体结合域串联二聚体的基因序列。
可选的,所述冠状病毒为2019-nCoV。
可选的,所述副流感病毒5型基因组为:用序列甲替换一种副流感病毒5型基因组的小疏水蛋白基因核苷酸序列,所得;
所述序列甲为如下1)或2)或3):
A)SEQ ID NO:1所示DNA分子;
B)在严格条件下与A)限定的DNA分子杂交且编码所述冠状病毒Spike蛋白的受体结合域串联二聚体的DNA序列;
C)与A)或B)限定的DNA序列具有99%以上、95%以上、90%以上、85%以上或者80%以上同一性且编码所述冠状病毒Spike蛋白的受体结合域串联二聚体的DNA序列。
可选的,所述表达冠状病毒Spike蛋白的受体结合域串联二聚体的基因序列如SEQID:NO:1所示;所述表达冠状病毒Spike蛋白的受体结合域串联二聚体基因序列编码的蛋白的氨基酸序列为SEQ ID:NO:2所示。
可选的,所述副流感病毒5型基因组为将SEQ ID NO:6所示的核苷酸序列的第6303-6437位的核苷酸序列替换为SEQ ID NO:1所示的核苷酸序列。
一种组合物,包括重组副流感病毒5型载体、表达辅助蛋白的辅助重组质粒—NP、辅助重组质粒—P和辅助重组质粒—L;所述表达辅助蛋白的辅助重组质粒—NP、辅助重组质粒—P和辅助重组质粒—L是将副流感病毒5型的NP、P和L蛋白的编码基因分别***哺乳动物表达载体中,得到辅助重组质粒—NP、辅助重组质粒—P和辅助重组质粒—L,。
可选的,NP蛋白的氨基酸序列如SEQ ID NO:3所示;P蛋白的氨基酸序列如SEQ IDNO:4所示;L蛋白的氨基酸序列如SEQ ID NO:5所示。
可选的,哺乳动物表达载体为pcDNA3.1(+)。
所述冠状病毒为2019-nCoV。
一种在细胞中表达冠状病毒Spike蛋白的受体结合域串联二聚体的方法,该方法包括使该细胞与上述的重组副流感病毒5型载体相接触。
一种表达冠状病毒Spike蛋白的受体结合域串联二聚体的重组副流感病毒5型载体的制备方法,包括如下步骤:
1)将副流感病毒5型全基因组反转录得到的cDNA***克隆载体中,得到重组质粒pPIV5;
2)用序列甲替换步骤1)中重组质粒pPIV5中副流感病毒5型的小疏水蛋白基因核苷酸序列;所述序列乙为如下1)或2)或3):
A)SEQ ID NO:1所示DNA分子;
B)在严格条件下与A)限定的DNA分子杂交且编码所述冠状病毒Spike蛋白的受体结合域串联二聚体的DNA序列;
C)与A)或B)限定的DNA序列具有99%以上、95%以上、90%以上、85%以上或者80%以上同一性且编码所述冠状病毒Spike蛋白的受体结合域串联二聚体的DNA序列。
可选的,步骤1)中所述克隆载体为带有T7 RNA聚合酶启动子序列、带有丁肝核酶序列、T7 RNA聚合酶转录终止序列的克隆载体。
一种新型冠状病毒(2019-nCoV)疫苗的制备方法,所述疫苗的制备方法包括如下步骤:将表达冠状病毒Spike蛋白的受体结合域串联二聚体的重组副流感病毒5型载体、表达辅助蛋白的辅助重组质粒—NP、辅助重组质粒—P和辅助重组质粒—L共转染宿主细胞。
可选的,所述宿主细胞为BSR-T7细胞,MDBK细胞,Vero细胞或BHK细胞。
上述方法制备得到的疫苗。
重组副流感病毒5型载体或上述方法制备的重组副流感病毒5型载体在如下任一一种中的应用:
(1)制备提高动物体内针对冠状病毒2019-nCoV Spike蛋白抗体水平的产品中的应用;
(2)制备预防或辅助预防冠状病毒2019-nCoV引起的疾病产品中的应用。
本发明技术方案,具有如下优点:
本发明提供一种表达冠状病毒Spike蛋白的受体结合域串联二聚体的重组副流感病毒5型载体,所述重组副流感病毒5型载体包含一种副流感病毒5型基因组,所述副流感病毒5型基因组包含冠状病毒Spike蛋白的受体结合域串联二聚体的基因序列。
实验第1、第15天,两次向BALB/c小鼠滴鼻接种疫苗(重组副流感病毒5型rPIV5-tr-RBD),免疫重组病毒rPIV5-tr-RBD组小鼠体内产生针对新冠病毒Spike蛋白的特异性抗体,而rPIV5对照组小鼠未能检测到针对新冠病毒Spike蛋白的特异性抗体。表明rPIV5-tr-RBD重组病毒免疫小鼠能够刺激小鼠产生针对Spike蛋白的特异性抗体。
实验第1、第15天,两次向BALB/c小鼠滴鼻接种rPIV5-tr-RBD,首免后6周,鼻腔接种2019-nCoV冠状病毒;小鼠攻毒后第3天剖杀,肺脏病原核酸检测结果表明2019-nCoV冠状病毒不能在小鼠肺脏中有效复制。rPIV5-tr-RBD对2019-nCoV冠状病毒具有优良的免疫保护效果。本发明具有重要的应用价值。
附图说明
为了更清楚地说明本发明具体实施方式或现有技术中的技术方案,下面将对具体实施方式或现有技术描述中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图是本发明的一些实施方式,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。
图1.利用RT-PCR对rPIV5-tr-RBD病毒基因组中二聚体RBD基因进行鉴定;
图2.利用间接免疫荧光对rPIV5-tr-RBD重组病毒感染细胞RBD蛋白表达情况进行鉴定;
图3.利用Western blot对rPIV5-tr-RBD重组病毒感染细胞RBD蛋白表达情况进行鉴定;
图4.ELISA检测小鼠免疫1-4周后血清中针对SARS-CoV-2Spike蛋白IgG抗体水平;
图5.qPCR检测新冠病毒S、N、ORF基因在感染免疫后小鼠肺脏中的RNA水平;
图6.重组质粒pPIV5的图谱。
具体实施方式
下述pBlueScript SK II(+)-1载体,公众可从申请人处获得,该生物材料只为重复本发明的相关实验所用,不可作为其它用途使用。
实施例1
1.重组副流感病毒5型的制备
1.1 PIV5反向遗传操作***质粒的构建
1、合成载体病毒PIV5为本实验室在山东省某猪场健康猪体内分离得到的病毒株(命名为CHNSD-011),利用Roche RNA提取试剂盒对该毒株提取RNA并利用PrimeScriptTM II1st Strand cDNA Synthesis Kit反转录,获得毒株的cDNA。将PIV5基因组全长15246nt(见SEQ ID NO:6)分为A-C共3个约5-5.5kb大小片段,A片段为PIV5基因组全长(5’-3’)的第1bp-5030bp,B片段为PIV5基因组全长(5’-3’)的第5016bp-9906bp,C片段为PIV5基因组全长(5’-3’)的第9892-15246bp。利用引物分别进行PCR扩增,将DNA片段回收后的A、B和C分别***pEasy-Blunt Zero载体,经测序确认序列无误后保留,三片段的质粒分别命名为pZero-A、pZero-B与pZero-C。
2、改造pBlueScript SK II(+)(优宝生物,货号为VT1328),改造后载体5’端带有T7 RNA聚合酶启动子序列,3’端带有丁肝核酶序列和T7 RNA聚合酶转录终止序列的pBlueScript SK II(+),其他序列不变,改造后的载体命名为pBlueScript SK II(+)-1,将步骤1中得到的三个质粒,利用引物进行PCR扩增,获得分为三段(A、B、C)的PIV5全基因组,将PIV5全基因组与pBlueScript SK II(+)-1进行同源重组连接,得到重组质粒pPIV5,重组质粒pPIV5图谱见图6(即在pBlueScript SK II(+)-1的多克隆位点***序列SEQ ID NO:6),测序验证正确并保留。
3、以pPIV5为模板,以SphI-F(SEQ ID NO:7)与SphI-R(SEQ ID NO:8)引物扩增片段SphI,并在片段3’端引入PmeI酶切位点;以BbvCI-F(SEQ ID NO:9)与BbvCI-R(SEQ IDNO:10)引物扩增片段BbvCI,并在引物5’端引入PmeI酶切位点,将两片段回收备用。
4、利用SphI-F与BbvCI-R引物扩增片段SphI和BbvCI,扩增得到的目的片段为将SphI和BbvCI片段中的小疏水蛋白基因替换为PmeI识别序列,命名为△SH(此步骤的目的为引入PmeI识别序列,删除小疏水蛋白基因)。
5、利用SphI与BbvCI双酶切pPIV5载体,回收后与片段△SH进行同源重组,获得携带有PmeI酶切位点的载体vPIV5-PmeI。vPIV5-PmeI载体为将重组质粒pPIV5中的小疏水蛋白基因(sh,为SEQ ID NO:6的第6303-6437位)替换为PmeI识别序列的片段,其他序列保持不变,得到的载体。
6、利用基因NP、P和L特异性引物对(NP的引物对为NP-F、NP-R;P的引物对为P-F、P-R;L的引物对为L-F、L-R),步骤2中得到的重组质粒pPIV5进行扩增,获得NP的基因序列为基因组全长152位到1681位(NP蛋白的氨基酸序列如SEQ ID NO:3所示),P的基因序列为基因组全长1850位到3026位(P蛋白的氨基酸序列如SEQ ID NO:4所示),L的基因序列为基因组全长序列8414位到15181位(L蛋白的氨基酸序列如SEQ ID NO:5所示)。将NP的基因序列***购自Invitrogen公司的pcDNA3.1(+)(货号:V790-20)的HindIII位点,获得可在真核细胞中表达病毒蛋白NP的重组质粒pcDNA-NP;将P的基因序列***pcDNA3.1(+)的HindIII位点,获得可在真核细胞中表达病毒蛋白P的重组质粒pcDNA-P;将L的基因序列***pcDNA3.1(+)的HindIII位点,获得可在真核细胞中表达病毒蛋白L的重组质粒pcDNA-L。
1.2重组病毒rPIV5感染性克隆的获得
1、将纯化提取所得步骤1.1中的pPIV5、pcDNA-NP、pcDNA-P与pcDNA-L共转染稳定表达T7 RNA聚合酶的BSR T7/5细胞。
2、完成步骤1后72h,将转染后的BSR T7/5细胞与上清置于-80℃冻融后,接种MDBK细胞,4h后更换为含有2%FBS的DMEM培养基。
3、完成步骤2后72h,吸取细胞上清液,接种新的MDBK细胞,4h后更换为含有2%FBS的DMEM培养基。
完成步骤3后72h,重复步骤3一次,取细胞上清接种至新的MDBK细胞。72h后,吸取MDBK细胞上清液进行血凝检测,能够产生血凝现象的上清液即为拯救成功的重组rPIV5,进行后续的检测与鉴定工作。
2.表达新冠病毒RBD二聚体蛋白的重组副流感病毒5型的制备
2.1表达RBD二聚体蛋白PIV5反向遗传操作***质粒的构建
1、利用Primestar HS高保真酶对新冠病毒Wuhan-1毒株Severe acuterespiratory syndrome coronavirus 2 isolate Wuhan-Hu-1表达Spike蛋白质粒pcDNA-Spike(受赠于博迈德公司,Spike Protein of SARS-CoV-2Activates Macrophages andContributes to Induction of Acute Lung Inflammations in Mice.https://doi.org/10.1101/2020.12.07.414706)进行扩增,分别使用引物RBD-di-1F、RBD-di-1R,RBD-di-2F、RBD-di-2R两引物对扩增RBD区域序列,扩增得到的两个DNA片段分别命名为R1和R2,电泳鉴定无误后对两个片段进行回收。
2、同一PCR反应体系中,利用引物RBD2-fu-F、RBD2-fu-R,以片段R1,R2为模板进行扩增,获得R1,R2片段融合产物RBD12(冠状病毒S蛋白的受体结合域二聚体基因),冠状病毒S蛋白(Spike蛋白)的受体结合域二聚体基因的序列见SEQ ID NO:1,将两融合片段产物电泳鉴定无误后回收DNA产物备用。
3、利用PmeI酶对携带有PmeI酶切位点的1.1中的vPIV5-PmeI载体进行酶切线性化处理,获得载体片段pPIV5-PmeI,将其回收备用。
4、以步骤3中的片段pPIV5-PmeI为载体,与步骤2中的RBD12片段进行同源重组连接,得到重组质粒rPIV5-tr-RBD,测序无误后保留备用。重组质粒rPIV5-tr-RBD为在vPIV5-PmeI载体的PmeI识别位点处***SEQ ID NO:1所示的DNA分子所得。
2.2表达RBD二聚体蛋白重组PIV5的拯救
1、将纯化提取所得2.1中的rPIV5-tr-RBD、pcDNA-NP、pcDNA-P与pcDNA-L四质粒共转染表达T7 RNA聚合酶的BSR T7/5细胞。
2、完成步骤1后72h,将BSR T7/5细胞与上清置于-80℃冻融后,接种MDBK细胞,4h后更换为含有2%FBS的DMEM培养基。
3、完成步骤2后72h,吸取细胞上清液,接种新的MDBK细胞,4h后更换为含有2%FBS的DMEM培养基。
4、完成步骤3后72h,重复步骤3一次,接种至新的MDBK细胞。72h后,吸取MDBK细胞上清液进行血凝检测,能够产生血凝的上清液即为拯救成功的重组rPIV5-tr-RBD,进行后续的检测与鉴定工作。
3.重组病毒rPIV5-tr-RBD的鉴定
一、基因鉴定
提取重组病毒rPIV5-tr-RBD基因组RNA,进行反转录获得cDNA后,利用引物SH-JF与SH-JR对(序列见下表)包含有***二聚体RBD基因的病毒基因组区域进行PCR扩增,获得PCR扩增产物。
表1
Figure BDA0002995071590000071
试验结果见图1,PCR扩增产物片段为1688bp,片段大小符合预期,经Sanger测序后确认,RBD二聚体基因序列已完全***PIV5基因组中,且序列准确无误。
二、间接免疫荧光鉴定
1、取12孔细胞培养板,加入1mL含有2X105个MDBK细胞的含10%FBS的DMEM培养液,于37℃、5%CO2培养过夜,至MDBK细胞长至90%密度。
2、完成步骤1后,利用pH为7.2、0.01M的PBS缓冲液清洗细胞两次,弃去液体,更换为含2%FBS的DMEM培养基1mL,并接种重组病毒rPIV5-tr-RBD 103TCID50,继续培养48h。
3、完成步骤2后,弃去细胞孔中上清,利用pH7.2、0.01M的PBS缓冲液洗涤2次,之后每孔加入1mL预冷的固定液(乙醇与丙酮按照3:2体积比混合配制而成),静置20min,进行细胞固定与透化。
4、完成步骤3后,弃去孔中液体,每孔利用1mL PBS缓冲液洗涤3次,每次5min;之后每孔加入500μL鼠抗PIV5稀释液,4℃过夜孵育8h。将鼠抗PIV5替换为兔抗SARS-CoV-2病毒Spike蛋白多克隆抗体稀释液进行实验,检测毒RBD二聚体蛋白的表达。两种抗体稀释液均由1体积份抗体和199体积份pH7.2、0.01M的PBS缓冲液混合而成(鼠抗PIV5稀释液购自武汉华美生物,货号:CSB-MA000160,兔抗SARS-CoV Spike蛋白抗体,购自义翘神州,货号为40150-T62-COV2)。
5、完成步骤4后,弃去液体,利用PBS缓冲液1mL洗涤3次,每次5min;而后加入TRITC基团标记的羊抗鼠二抗稀释液(该稀释液的制备方法为将羊抗鼠二抗(以1:400体积比利用PBS缓冲液稀释)进行抗原抗体结合染色,37℃避光孵育1h。羊抗鼠二抗购自BioVision公司,货号:6921-100。
6、完成步骤5后,弃去孔内液体,利用PBS缓冲液1mL洗涤3次,每次5min;而后加入FITC基团标记的羊抗兔二抗稀释液(该稀释液的制备方法为将羊抗兔二抗以1:200体积比利用PBS缓冲液稀释),进行抗原抗体结合染色,37℃避光孵育1h。羊抗兔二抗购自碧云天生物技术有限公司,货号:A0562。
7、完成步骤6后,弃去孔内液体,利用PBST缓冲液1mL洗涤3次,每次5min,最后一次保留孔内PBST缓冲液不弃去,置于倒置荧光显微镜下观察。将重组病毒rPIV5-tr-RBD替换为重组野生病毒rPIV5作为对照。
试验结果见图2。结果表明,重组病毒rPIV5-tr-RBD感染MDBK细胞48h后,可在细胞中检测到表达的PIV5 P蛋白(红色)与新冠病毒RBD二聚体蛋白(绿色);而重组野生病毒rPIV5感染细胞后仅能检测到PIV5 P蛋白(红色),不能检测到新冠病毒RBD二聚体蛋白的表达。
三、Western blot鉴定
1、取6孔细胞培养板,加入2mL含有MDBK细胞的细胞培养液(约4×105个MDBK细胞/孔),37℃、5%CO2培养过夜,直至MDBK细胞生长成单层至约90%密度。
2、完成步骤1后,利用2mL PBS洗涤细胞三次,接种重组病毒rPIV5-tr-RBD或rPIV5(接种剂量为104TCID50)并更换为含2%FBS的DMEM培养液,37℃、5%CO2培养48h。
3、取完成步骤2的细胞,PBS洗涤三次后,使用胰蛋白酶消化后,离心,收集细胞。
4、完成步骤3后,取所述细胞,利用IP裂解液进行裂解,得到细胞裂解液,10000g离心10min后小心吸取上清,加入Western Protein Loading Buffer,100℃变性10min后冷却至室温。
5、完成步骤4后,将所述细胞裂解液进行SDS-PAGE和Western blot,采用兔抗新冠病毒Spike蛋白多克隆抗体(Sino Biological公司,0150-T62-COV2)作为一抗、辣根过氧化物酶(HRP)标记的羊抗兔抗体(碧云天生物技术有限公司,货号:A0208)作为二抗检测RBD二聚体蛋白;利用PIV5 P蛋白作为内参,鼠抗P蛋白V5标签单克隆抗体(武汉华美生物技术有限公司,货号:CSB-MA000160)为一抗,HRP标记羊抗鼠抗体(Abcam公司,货号:ab6789)作为二抗。
实验结果见图3。结果表明,重组病毒rPIV5-tr-RBD感染的MDBK细胞中能够在60KD大小位置检测RBD二聚体蛋白特异性条带,而rPIV5感染的MDBK细胞中未检测到该特异性条带,表明重组病毒rPIV5tr-RBD感染细胞后可表达新冠病毒二聚体化RBD蛋白。
4、重组病毒rPIV5-tr-RBD对新冠病毒SARS-CoV-2的免疫保护效果评价
将20只6周龄BALB/c小鼠随机分成两组,每组10只。实验组鼻腔接种50μL重组病毒rPIV5-tr-RBD,对照组鼻腔接种50μL重组病毒rPIV5,接种剂量均为106TCID50/只。首次接种后15天,重复上述操作一次。免疫后持续观察每组小鼠的临床症状:包括是否出现食欲不振,被毛凌乱,呼吸困难和活动量减少行为。
观察发现,rPIV5对照组与rPIV5-tr-RBD免疫组均未出现明显的临床症状,饮食正常,体重保持相对稳定。表明本研究构建的重组rPIV5及表达新冠病毒Spike蛋白RBD区域二聚体蛋白的rPIV5-tr-RBD重组毒对小鼠无副反应或不良反应,安全性良好。
在首次免疫后每间隔7天利用眼眶后静脉丛法采集小鼠血液,37℃静置50min,8000rpm离心15min,收集血清,分装后-80℃保存。利用间接ELISA方法对小鼠体内针对Spike蛋白抗体水平进行检测。
间接ELISA方法的步骤为:
1)包板,用ELISA coating buffer(索莱宝公司,C1055)稀释SARS-2-S(Vazyme,货号:CG202-00)到1μg/mL,每孔加50μL,4℃孵育过夜。
2)移除抗原溶液,用PBS清洗3次。
3)封闭,每孔加100μL封闭液(含5%脱脂乳PBS缓冲液),在37℃孵育至少1小时。
4)移除封闭液,用PBS洗板3次;
5)用血清孵育,用抗体稀释液(即封闭液)稀释血清到正确的比例,小鼠血清稀释从1:25开始,按照排板要求,孔里加入100μL血清稀释液,在37℃孵育2小时,阴性对照为健康鼠的血清,阳性对照要确保检测出来。
6)移除血清稀释液,用PBST洗板5次。
7)用2抗(HRP-conjugated goat anti-mouse IgG,Abcam公司,货号ab6789)孵育,2抗用抗体稀释缓冲液稀释,anti-mouse IgG的稀释比例是1:5000,按照排板要求,孔里加入100μL 2抗稀释液,在37℃孵育1.5小时。
8)移除2抗缓冲液,用PBST洗板5次。
9)每孔加入100μL TMB显色液(Beyotime,P0209),轻微拍打孔板,使其混合均匀,在室温孵育一段时间,当阴性孔有变蓝的趋势时,每孔加入100μL终止液,终止反应。
10)用酶标仪在450nm处记录吸光值。
试验结果详见图4(图4中的“免疫后1、2、3、4周”均指“首免后”),结果表明,免疫重组病毒rPIV5-tr-RBD组小鼠体内产生抗体针对新冠病毒Spike蛋白的特异性抗体,而rPIV5对照组小鼠未能检测到针对新冠病毒Spike蛋白的特异性抗体。表明rPIV5-tr-RBD重组病毒免疫小鼠能够刺激小鼠产生针对Spike蛋白的特异性抗体。
首免后6周,每只小鼠滴鼻感染新冠病毒SARS-CoV-2,接种剂量104TCID50,之后每天观察小鼠的临床症状,称量体重,并在攻毒后第3天,每组各剖检5只小鼠,采集小鼠肺脏,研磨组织,取上清液提取RNA后利用实时荧光定量PCR方法检测新冠病毒RNA在小鼠脏器中的水平,结果(图5)表明,新冠病毒无法在小鼠肺脏中复制,rPIV5-tr-RBD具有良好的免疫保护效果。
显然,上述实施例仅仅是为清楚地说明所作的举例,而并非对实施方式的限定。对于所属领域的普通技术人员来说,在上述说明的基础上还可以做出其它不同形式的变化或变动。这里无需也无法对所有的实施方式予以穷举。而由此所引伸出的显而易见的变化或变动仍处于本发明创造的保护范围之中。
序列表
<110> 中国农业大学
<120> 一种表达冠状病毒受体结合域串联二聚体的重组副流感病毒5型载体
<160> 12
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1368
<212> DNA
<213> 人工序列
<400> 1
atgatacact cagtgtttct actgatgttc ttgttaacac ctacagaaag tagagtccaa 60
ccaacagaat ctattgttag atttcctaat attacaaact tgtgcccttt tggtgaagtt 120
tttaacgcca ccagatttgc atctgtttat gcttggaaca ggaagagaat cagcaactgt 180
gttgctgatt attctgtcct atataattcc gcatcatttt ccacttttaa gtgttatgga 240
gtgtctccta ctaaattaaa tgatctctgc tttactaatg tctatgcaga ttcatttgta 300
attagaggtg atgaagtcag acaaatcgct ccagggcaaa ctggaaagat tgctgattat 360
aattataaat taccagatga ttttacaggc tgcgttatag cttggaattc taacaatctt 420
gattctaagg ttggtggtaa ttataattac ctgtatagat tgtttaggaa gtctaatctc 480
aaaccttttg agagagatat ttcaactgaa atctatcagg ccggtagcac accttgtaat 540
ggtgttgaag gttttaattg ttactttcct ttacaatcat atggtttcca acccactaat 600
ggtgttggtt accaaccata cagagtagta gtactttctt ttgaacttct acatgcacca 660
gcaactgttt gtggacctaa aaagtctact aatttggtta aaaacaaaag agtccaacca 720
acagaatcta ttgttagatt tcctaatatt acaaacttgt gcccttttgg tgaagttttt 780
aacgccacca gatttgcatc tgtttatgct tggaacagga agagaatcag caactgtgtt 840
gctgattatt ctgtcctata taattccgca tcattttcca cttttaagtg ttatggagtg 900
tctcctacta aattaaatga tctctgcttt actaatgtct atgcagattc atttgtaatt 960
agaggtgatg aagtcagaca aatcgctcca gggcaaactg gaaagattgc tgattataat 1020
tataaattac cagatgattt tacaggctgc gttatagctt ggaattctaa caatcttgat 1080
tctaaggttg gtggtaatta taattacctg tatagattgt ttaggaagtc taatctcaaa 1140
ccttttgaga gagatatttc aactgaaatc tatcaggccg gtagcacacc ttgtaatggt 1200
gttgaaggtt ttaattgtta ctttccttta caatcatatg gtttccaacc cactaatggt 1260
gttggttacc aaccatacag agtagtagta ctttcttttg aacttctaca tgcaccagca 1320
actgtttgtg gacctaaaaa gtctactaat ttggttaaaa acaaataa 1368
<210> 2
<211> 455
<212> PRT
<213> 人工序列
<400> 2
Met Ile His Ser Val Phe Leu Leu Met Phe Leu Leu Thr Pro Thr Glu
1 5 10 15
Ser Arg Val Gln Pro Thr Glu Ser Ile Val Arg Phe Pro Asn Ile Thr
20 25 30
Asn Leu Cys Pro Phe Gly Glu Val Phe Asn Ala Thr Arg Phe Ala Ser
35 40 45
Val Tyr Ala Trp Asn Arg Lys Arg Ile Ser Asn Cys Val Ala Asp Tyr
50 55 60
Ser Val Leu Tyr Asn Ser Ala Ser Phe Ser Thr Phe Lys Cys Tyr Gly
65 70 75 80
Val Ser Pro Thr Lys Leu Asn Asp Leu Cys Phe Thr Asn Val Tyr Ala
85 90 95
Asp Ser Phe Val Ile Arg Gly Asp Glu Val Arg Gln Ile Ala Pro Gly
100 105 110
Gln Thr Gly Lys Ile Ala Asp Tyr Asn Tyr Lys Leu Pro Asp Asp Phe
115 120 125
Thr Gly Cys Val Ile Ala Trp Asn Ser Asn Asn Leu Asp Ser Lys Val
130 135 140
Gly Gly Asn Tyr Asn Tyr Leu Tyr Arg Leu Phe Arg Lys Ser Asn Leu
145 150 155 160
Lys Pro Phe Glu Arg Asp Ile Ser Thr Glu Ile Tyr Gln Ala Gly Ser
165 170 175
Thr Pro Cys Asn Gly Val Glu Gly Phe Asn Cys Tyr Phe Pro Leu Gln
180 185 190
Ser Tyr Gly Phe Gln Pro Thr Asn Gly Val Gly Tyr Gln Pro Tyr Arg
195 200 205
Val Val Val Leu Ser Phe Glu Leu Leu His Ala Pro Ala Thr Val Cys
210 215 220
Gly Pro Lys Lys Ser Thr Asn Leu Val Lys Asn Lys Arg Val Gln Pro
225 230 235 240
Thr Glu Ser Ile Val Arg Phe Pro Asn Ile Thr Asn Leu Cys Pro Phe
245 250 255
Gly Glu Val Phe Asn Ala Thr Arg Phe Ala Ser Val Tyr Ala Trp Asn
260 265 270
Arg Lys Arg Ile Ser Asn Cys Val Ala Asp Tyr Ser Val Leu Tyr Asn
275 280 285
Ser Ala Ser Phe Ser Thr Phe Lys Cys Tyr Gly Val Ser Pro Thr Lys
290 295 300
Leu Asn Asp Leu Cys Phe Thr Asn Val Tyr Ala Asp Ser Phe Val Ile
305 310 315 320
Arg Gly Asp Glu Val Arg Gln Ile Ala Pro Gly Gln Thr Gly Lys Ile
325 330 335
Ala Asp Tyr Asn Tyr Lys Leu Pro Asp Asp Phe Thr Gly Cys Val Ile
340 345 350
Ala Trp Asn Ser Asn Asn Leu Asp Ser Lys Val Gly Gly Asn Tyr Asn
355 360 365
Tyr Leu Tyr Arg Leu Phe Arg Lys Ser Asn Leu Lys Pro Phe Glu Arg
370 375 380
Asp Ile Ser Thr Glu Ile Tyr Gln Ala Gly Ser Thr Pro Cys Asn Gly
385 390 395 400
Val Glu Gly Phe Asn Cys Tyr Phe Pro Leu Gln Ser Tyr Gly Phe Gln
405 410 415
Pro Thr Asn Gly Val Gly Tyr Gln Pro Tyr Arg Val Val Val Leu Ser
420 425 430
Phe Glu Leu Leu His Ala Pro Ala Thr Val Cys Gly Pro Lys Lys Ser
435 440 445
Thr Asn Leu Val Lys Asn Lys
450 455
<210>3
<211> 508
<212> PRT
<213> 人工序列
<400> 3
Met Ser Ser Val Leu Lys Ala Tyr Glu Arg Phe Thr Leu Thr Gln Glu
1 5 10 15
Leu Gln Asp Gln Ser Glu Glu Gly Thr Ile Pro Pro Thr Thr Leu Lys
20 25 30
Pro Val Ile Arg Val Phe Ile Leu Thr Ser Asn Asn Pro Glu Leu Arg
35 40 45
Ser Arg Leu Leu Leu Phe Cys Leu Arg Ile Val Leu Ser Asn Gly Ala
50 55 60
Arg Asp Ser His Arg Phe Gly Ala Leu Leu Thr Met Phe Ser Leu Pro
65 70 75 80
Ser Ala Thr Met Leu Asn His Val Lys Leu Ala Asp Gln Ser Pro Glu
85 90 95
Ala Asp Ile Glu Arg Val Glu Ile Asp Gly Phe Glu Glu Gly Ser Phe
100 105 110
Arg Leu Ile Pro Asn Ala Arg Ser Gly Met Ser Arg Gly Glu Ile Asn
115 120 125
Ala Tyr Ala Ala Leu Ala Glu Asp Leu Pro Asp Thr Leu Asn His Ala
130 135 140
Thr Pro Phe Val Asp Ser Glu Val Glu Gly Thr Ala Trp Asp Glu Ile
145 150 155 160
Glu Thr Phe Leu Asp Met Cys Tyr Ser Val Leu Met Gln Ala Trp Ile
165 170 175
Val Thr Cys Lys Cys Met Thr Ala Pro Asp Gln Pro Ala Ala Ser Ile
180 185 190
Glu Lys Arg Leu Gln Lys Tyr Arg Gln Gln Gly Arg Ile Asn Pro Arg
195 200 205
Tyr Leu Leu Gln Pro Glu Ala Arg Arg Ile Ile Gln Asn Val Ile Arg
210 215 220
Lys Gly Met Val Val Arg His Phe Leu Thr Phe Glu Leu Gln Leu Ala
225 230 235 240
Arg Ala Gln Ser Leu Val Ser Asn Arg Tyr Tyr Ala Met Val Gly Asp
245 250 255
Val Gly Lys Tyr Ile Glu Asn Cys Gly Met Gly Gly Phe Phe Leu Thr
260 265 270
Leu Lys Tyr Ala Leu Gly Thr Arg Trp Pro Thr Leu Ala Leu Ala Ala
275 280 285
Phe Ser Gly Glu Leu Thr Lys Leu Lys Ser Leu Met Ala Leu Tyr Gln
290 295 300
Thr Leu Gly Glu Gln Ala Arg Tyr Leu Ala Leu Leu Glu Ser Pro His
305 310 315 320
Leu Met Asp Phe Ala Ala Ala Asn Tyr Pro Leu Leu Tyr Ser Tyr Ala
325 330 335
Met Gly Ile Gly Tyr Val Leu Asp Val Asn Met Arg Asn Tyr Ala Phe
340 345 350
Ser Arg Ser Tyr Met Asn Lys Thr Tyr Phe Gln Leu Gly Met Glu Thr
355 360 365
Ala Arg Lys Gln Gln Gly Ala Val Asp Met Arg Met Ala Glu Asp Leu
370 375 380
Gly Leu Thr Gln Ala Glu Arg Thr Glu Met Ala Asn Thr Leu Ala Lys
385 390 395 400
Leu Thr Thr Ala Asn Arg Gly Ala Asp Thr Arg Gly Gly Val Asn Pro
405 410 415
Phe Ser Ser Val Thr Gly Thr Thr Gln Val Pro Ala Ala Ala Thr Gly
420 425 430
Asp Thr Leu Glu Ser Tyr Met Ala Ala Asp Arg Leu Arg Gln Arg Tyr
435 440 445
Ala Asp Ala Gly Thr His Asp Asp Glu Met Pro Pro Leu Glu Glu Glu
450 455 460
Glu Glu Asp Asp Thr Ser Ala Gly Pro Arg Thr Gly Pro Thr Leu Glu
465 470 475 480
Gln Val Ala Leu Asp Ile Gln Asn Ala Ala Val Gly Ala Pro Ile His
485 490 495
Thr Asp Asp Leu Asn Ala Ala Leu Gly Asp Leu Asp
500 505
<210>4
<211> 392
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 4
Met Asp Pro Thr Asp Leu Ser Phe Ser Pro Asp Glu Ile Asn Lys Leu
1 5 10 15
Ile Glu Thr Gly Leu Asn Thr Val Glu Tyr Leu Thr Ser Gln Gln Val
20 25 30
Thr Gly Thr Ser Ser Leu Gly Lys Asn Thr Ile Pro Pro Gly Val Thr
35 40 45
Gly Leu Pro Thr Asn Ala Ala Glu Ala Lys Ile Gln Glu Ser Thr Asn
50 55 60
His Gln Lys Gly Ser Val Gly Gly Gly Ala Lys Pro Lys Lys Pro Arg
65 70 75 80
Pro Lys Ile Ala Ile Val Pro Ala Asp Asp Lys Thr Val Pro Gly Lys
85 90 95
Pro Ile Pro Asn Pro Leu Leu Gly Leu Asp Ser Thr Pro Ser Thr Gln
100 105 110
Thr Val Leu Asp Leu Ser Gly Lys Thr Leu Pro Ser Gly Ser Tyr Lys
115 120 125
Gly Val Lys Leu Ala Asn Phe Gly Lys Glu Asn Leu Met Thr Arg Phe
130 135 140
Ile Glu Glu Pro Arg Glu Asn Pro Ile Ala Thr Asn Ser Pro Ile Asp
145 150 155 160
Phe Lys Arg Gly Ala Gly Ile Pro Ala Gly Ser Ile Glu Gly Ser Thr
165 170 175
Gln Ser Asp Gly Trp Glu Met Lys Ser Arg Ser Leu Ser Gly Ala Ile
180 185 190
His Pro Val Leu Gln Ser Pro Leu Gln Gln Gly Asp Leu Asn Ala Leu
195 200 205
Val Thr Ser Val Gln Ser Leu Ala Leu Asn Val Asn Glu Ile Leu Asn
210 215 220
Thr Val Arg Asn Leu Asp Ser Arg Met Asn Gln Leu Glu Thr Lys Val
225 230 235 240
Asp Arg Ile Leu Ser Ser Gln Ser Leu Ile Gln Thr Ile Lys Asn Asp
245 250 255
Ile Val Gly Leu Lys Ala Gly Met Ala Thr Leu Glu Gly Met Ile Thr
260 265 270
Thr Val Lys Ile Met Asp Pro Gly Val Pro Ser Asn Ile Thr Val Glu
275 280 285
Asp Val Arg Lys Lys Leu Ser Asn His Ala Val Val Val Pro Glu Ser
290 295 300
Phe Asn Asp Ser Phe Leu Thr Gln Ser Glu Asp Val Ile Ser Leu Asp
305 310 315 320
Glu Leu Ala Arg Pro Thr Ala Thr Ser Val Lys Lys Ile Val Arg Lys
325 330 335
Val Pro Pro Gln Lys Asp Leu Thr Gly Leu Lys Ile Thr Leu Glu Gln
340 345 350
Leu Ala Lys Asp Cys Ile Ser Lys Pro Lys Met Arg Glu Glu Tyr Leu
355 360 365
Leu Lys Ile Asn Gln Ala Ser Ser Glu Ala Gln Leu Ile Asp Leu Lys
370 375 380
Lys Ala Ile Ile Arg Ser Ala Ile
385 390
<210> 5
<211> 2255
<212> PRT
<213> 人工序列
<400> 5
Met Ala Gly Ser Arg Glu Ile Leu Leu Pro Glu Val His Leu Asn Ser
1 5 10 15
Pro Ile Val Lys His Lys Leu Tyr Tyr Tyr Ile Leu Leu Gly Asn Leu
20 25 30
Pro Asn Glu Ile Asp Ile Asp Asp Leu Gly Pro Leu His Asn Gln Asn
35 40 45
Trp Asn Gln Ile Ala His Glu Glu Ser Asn Leu Ala Gln Arg Leu Val
50 55 60
Asn Val Arg Asn Phe Leu Ile Thr His Ile Ser Asp Leu Arg Lys Gly
65 70 75 80
His Trp Gln Glu Tyr Val Asn Val Ile Leu Trp Pro Arg Ile Leu Pro
85 90 95
Leu Ile Pro Asp Phe Lys Ile Asn Asp Gln Leu Pro Leu Leu Lys Asn
100 105 110
Trp Asp Lys Leu Val Lys Glu Ser Cys Ser Val Ile Asn Ala Gly Thr
115 120 125
Ser Gln Cys Ile Gln Asn Leu Ser Tyr Gly Leu Thr Gly Arg Gly Asn
130 135 140
Leu Phe Thr Arg Ser Arg Glu Leu Ser Gly Asp Arg Arg Asp Ile Asp
145 150 155 160
Leu Lys Thr Val Val Ala Ala Trp His Asp Ser Asp Trp Lys Arg Ile
165 170 175
Ser Asp Phe Trp Ile Met Ile Lys Phe Gln Met Arg Gln Leu Ile Val
180 185 190
Arg Gln Thr Asp His Asn Asp Pro Asp Leu Ile Thr Tyr Ile Glu Asn
195 200 205
Arg Glu Gly Ile Ile Ile Ile Thr Pro Glu Leu Val Ala Leu Phe Asn
210 215 220
Thr Glu Asn His Thr Leu Thr Tyr Met Thr Phe Glu Ile Val Leu Met
225 230 235 240
Val Ser Asp Met Tyr Glu Gly Arg His Asn Ile Leu Ser Leu Cys Thr
245 250 255
Val Ser Thr Tyr Leu Asn Pro Leu Lys Lys Arg Ile Lys Tyr Leu Leu
260 265 270
Ser Leu Val Asp Asn Leu Ala Phe Gln Ile Gly Asp Ala Val Tyr Asn
275 280 285
Ile Ile Ala Leu Leu Glu Ser Phe Val Tyr Ala Gln Leu Gln Met Ser
290 295 300
Asp Pro Ile Pro Glu Leu Arg Gly Gln Phe His Ala Phe Val Cys Ser
305 310 315 320
Glu Ile Leu Asp Ala Leu Arg Gly Thr Asn Ser Phe Thr Gln Asp Glu
325 330 335
Ser Arg Thr Val Thr Thr Asn Leu Ile Ser Pro Phe Gln Asp Leu Thr
340 345 350
Pro Asp Leu Thr Ala Glu Leu Leu Cys Ile Met Arg Leu Trp Gly His
355 360 365
Pro Met Leu Thr Ala Ser Gln Ala Ala Gly Lys Val Arg Glu Ser Met
370 375 380
Cys Ala Gly Lys Val Leu Asp Phe Pro Thr Ile Met Lys Thr Leu Ala
385 390 395 400
Phe Phe His Thr Ile Leu Ile Asn Gly Tyr Arg Arg Lys His His Gly
405 410 415
Val Trp Pro Pro Leu Asn Leu Pro Gly Asn Ala Ser Lys Gly Leu Thr
420 425 430
Glu Leu Met Asn Asp Asn Thr Glu Ile Ser Tyr Glu Phe Thr Leu Lys
435 440 445
His Trp Lys Glu Ile Ser Leu Ile Lys Phe Lys Lys Cys Phe Asp Ala
450 455 460
Asp Ala Gly Glu Glu Leu Ser Ile Phe Met Lys Asp Lys Ala Ile Ser
465 470 475 480
Ala Pro Lys Gln Asp Trp Met Ser Val Phe Arg Arg Ser Leu Ile Lys
485 490 495
Gln Arg His Gln His His Gln Val Pro Leu Pro Asn Pro Phe Asn Arg
500 505 510
Arg Leu Leu Leu Asn Phe Leu Gly Asp Asp Lys Phe Asp Pro Asn Val
515 520 525
Glu Leu Gln Tyr Val Thr Ser Gly Glu Tyr Leu His Asp Asp Thr Phe
530 535 540
Cys Ala Ser Tyr Ser Leu Lys Glu Lys Glu Ile Lys Pro Asp Gly Arg
545 550 555 560
Ile Phe Ala Lys Leu Thr Lys Arg Met Arg Ser Cys Gln Val Ile Ala
565 570 575
Glu Ser Leu Leu Ala Asn His Ala Gly Lys Leu Met Lys Glu Asn Gly
580 585 590
Val Val Met Asn Gln Leu Ser Leu Thr Lys Ser Leu Leu Thr Met Ser
595 600 605
Gln Ile Gly Ile Ile Ser Glu Lys Ala Arg Lys Ser Thr Arg Asp Asn
610 615 620
Ile Asn Gln Pro Gly Phe Gln Asn Ile Gln Arg Asn Lys Ser His His
625 630 635 640
Ser Lys Gln Val Asn Gln Arg Asp Pro Ser Asp Asp Phe Glu Leu Ala
645 650 655
Ala Ser Phe Leu Thr Thr Asp Leu Lys Lys Tyr Cys Leu Gln Trp Arg
660 665 670
Tyr Gln Thr Ile Ile Pro Phe Ala Gln Ser Leu Asn Arg Met Tyr Gly
675 680 685
Tyr Pro His Leu Phe Glu Trp Ile His Leu Arg Leu Met Arg Ser Thr
690 695 700
Leu Tyr Val Gly Asp Pro Phe Asn Pro Pro Ala Asp Thr Ser Gln Phe
705 710 715 720
Asp Leu Asp Lys Val Ile Asn Gly Asp Ile Phe Ile Val Ser Pro Arg
725 730 735
Gly Gly Ile Glu Gly Leu Cys Gln Lys Ala Trp Thr Met Ile Ser Ile
740 745 750
Ser Val Ile Ile Leu Ser Ala Thr Glu Ser Gly Thr Arg Val Met Ser
755 760 765
Met Val Gln Gly Asp Asn Gln Ala Ile Ala Val Thr Thr Arg Val Pro
770 775 780
Arg Ser Leu Pro Thr Leu Glu Lys Lys Thr Ile Ala Phe Arg Ser Cys
785 790 795 800
Asn Leu Phe Phe Glu Arg Leu Lys Cys Asn Asn Phe Gly Leu Gly His
805 810 815
His Leu Lys Glu Gln Glu Thr Ile Ile Ser Ser His Phe Phe Val Tyr
820 825 830
Ser Lys Arg Ile Phe Tyr Gln Gly Arg Ile Leu Thr Gln Ala Leu Lys
835 840 845
Asn Ala Ser Lys Leu Cys Leu Thr Ala Asp Val Leu Gly Glu Cys Thr
850 855 860
Gln Ser Ser Cys Ser Asn Leu Ala Thr Thr Val Met Arg Leu Thr Glu
865 870 875 880
Asn Gly Val Glu Lys Asp Ile Cys Phe Tyr Leu Asn Ile Tyr Met Thr
885 890 895
Ile Lys Gln Leu Ser Tyr Asp Ile Ile Phe Pro Gln Val Ser Ile Pro
900 905 910
Gly Asp Gln Ile Thr Leu Glu Tyr Ile Asn Asn Pro His Leu Val Ser
915 920 925
Arg Leu Ala Leu Leu Pro Ser Gln Leu Gly Gly Leu Asn Tyr Leu Ser
930 935 940
Cys Ser Arg Leu Phe Asn Arg Asn Ile Gly Asp Pro Val Val Ser Ala
945 950 955 960
Val Ala Asp Leu Lys Arg Leu Ile Lys Ser Gly Cys Met Asp Tyr Trp
965 970 975
Ile Leu Tyr Asn Leu Leu Gly Arg Lys Pro Gly Asn Gly Ser Trp Ala
980 985 990
Thr Leu Ala Ala Asp Pro Tyr Ser Ile Asn Ile Glu Tyr Gln Tyr Pro
995 1000 1005
Pro Thr Thr Ala Leu Lys Arg His Thr Gln Gln Ala Leu Met Glu
1010 1015 1020
Leu Ser Thr Asn Pro Met Leu Arg Gly Ile Phe Ser Asp Asn Ala
1025 1030 1035
Gln Ala Glu Glu Asn Asn Leu Ala Arg Phe Leu Leu Asp Arg Glu
1040 1045 1050
Val Ile Phe Pro Arg Val Ala His Ile Ile Ile Glu Gln Thr Ser
1055 1060 1065
Val Gly Arg Arg Lys Gln Ile Gln Gly Tyr Leu Asp Ser Thr Arg
1070 1075 1080
Ser Ile Met Ser Lys Ser Leu Glu Ile Lys Pro Leu Ser Asn Arg
1085 1090 1095
Lys Leu Asn Glu Ile Leu Asp Tyr Asn Ile Asn Tyr Leu Ala Tyr
1100 1105 1110
Asn Leu Ala Leu Leu Lys Asn Ala Ile Glu Pro Pro Thr Tyr Leu
1115 1120 1125
Lys Ala Met Thr Leu Glu Thr Cys Ser Ile Asp Ile Ala Arg Ser
1130 1135 1140
Leu Arg Lys Leu Ser Trp Ala Pro Leu Leu Gly Gly Arg Asn Leu
1145 1150 1155
Glu Gly Leu Glu Thr Pro Asp Pro Ile Glu Ile Thr Ala Gly Ala
1160 1165 1170
Leu Ile Val Gly Ser Gly Tyr Cys Glu Gln Cys Ala Ala Gly Asp
1175 1180 1185
Asn Arg Phe Thr Trp Phe Phe Leu Pro Ser Gly Ile Glu Ile Gly
1190 1195 1200
Gly Asp Pro Arg Asp Asn Pro Pro Ile Arg Val Pro Tyr Ile Gly
1205 1210 1215
Ser Arg Thr Asp Glu Arg Arg Val Ala Ser Met Ala Tyr Ile Arg
1220 1225 1230
Gly Ala Ser Ser Ser Leu Lys Ala Val Leu Arg Leu Ala Gly Val
1235 1240 1245
Tyr Ile Trp Ala Phe Gly Asp Thr Leu Glu Asn Trp Ile Asp Ala
1250 1255 1260
Leu Asp Leu Ser His Thr Arg Val Asn Ile Thr Leu Glu Gln Leu
1265 1270 1275
Gln Ser Leu Thr Pro Leu Pro Thr Ser Ala Asn Leu Thr His Arg
1280 1285 1290
Leu Asp Asp Gly Thr Thr Thr Leu Lys Phe Thr Pro Ala Ser Ser
1295 1300 1305
Tyr Thr Phe Ser Ser Phe Thr His Ile Ser Asn Asp Glu Gln Tyr
1310 1315 1320
Leu Thr Ile Asn Asp Lys Thr Ala Asp Ser Asn Ile Ile Tyr Gln
1325 1330 1335
Gln Leu Met Ile Thr Gly Leu Gly Ile Leu Glu Thr Trp Asn Asn
1340 1345 1350
Pro Pro Ile Asn Arg Thr Phe Glu Glu Ser Thr Leu His Leu His
1355 1360 1365
Thr Gly Ala Ser Cys Cys Val Arg Pro Val Asp Ser Cys Ile Ile
1370 1375 1380
Ser Glu Ala Leu Thr Val Lys Pro His Ile Thr Val Pro Tyr Ser
1385 1390 1395
Asn Lys Phe Val Phe Asp Glu Asp Pro Leu Ser Glu Tyr Glu Thr
1400 1405 1410
Ala Lys Leu Glu Ser Leu Ser Phe Gln Ala Gln Leu Gly Asn Ile
1415 1420 1425
Asp Ala Val Asp Met Thr Gly Lys Leu Thr Leu Leu Ser Gln Phe
1430 1435 1440
Thr Ala Arg Gln Ile Ile Asn Ala Ile Thr Gly Leu Asp Glu Ser
1445 1450 1455
Val Ser Leu Thr Asn Asp Ala Ile Val Ala Ser Asp Tyr Val Ser
1460 1465 1470
Asn Trp Ile Ser Glu Cys Met Tyr Thr Lys Leu Asp Glu Leu Phe
1475 1480 1485
Met Tyr Cys Gly Trp Glu Leu Leu Leu Glu Leu Ser Tyr Gln Met
1490 1495 1500
Tyr Tyr Leu Arg Val Val Gly Trp Ser Asn Ile Val Asp Tyr Ser
1505 1510 1515
Tyr Met Ile Leu Arg Arg Ile Pro Gly Ala Ala Leu Asn Asn Leu
1520 1525 1530
Ala Ser Thr Leu Ser His Pro Lys Leu Phe Arg Arg Ala Ile Asn
1535 1540 1545
Leu Asp Ile Val Ala Pro Leu Asn Ala Pro His Phe Ala Ser Leu
1550 1555 1560
Asp Tyr Ile Lys Met Ser Val Asp Ala Ile Leu Trp Gly Cys Lys
1565 1570 1575
Arg Val Ile Asn Val Ile Ser Asn Gly Gly Asp Leu Glu Leu Val
1580 1585 1590
Val Thr Ser Glu Asp Ser Leu Ile Leu Ser Asp Arg Ser Met Asn
1595 1600 1605
Leu Ile Ala Arg Lys Leu Thr Leu Leu Ser Leu Ile His His Asn
1610 1615 1620
Gly Leu Glu Leu Pro Lys Ile Lys Gly Phe Ser Pro Asp Glu Lys
1625 1630 1635
Cys Phe Ala Leu Thr Glu Phe Leu Arg Lys Val Val Asn Ser Gly
1640 1645 1650
Leu Ser Ser Ile Glu Asn Leu Ser Asn Phe Met Tyr Asn Val Glu
1655 1660 1665
Asn Pro Arg Leu Ala Ala Phe Ala Ser Asn Asn Tyr Tyr Leu Thr
1670 1675 1680
Arg Lys Leu Leu Asn Ser Ile Arg Asp Thr Glu Ser Gly Gln Val
1685 1690 1695
Ala Val Thr Ser Tyr Tyr Glu Ser Leu Glu Tyr Ile Asp Ser Leu
1700 1705 1710
Lys Leu Thr Pro His Val Pro Gly Thr Ser Cys Ile Glu Asp Asp
1715 1720 1725
Ser Leu Cys Thr Asn Asp Tyr Ile Ile Trp Ile Ile Glu Ser Asn
1730 1735 1740
Ala Asn Leu Glu Lys Tyr Pro Ile Pro Asn Ser Pro Glu Asp Asp
1745 1750 1755
Ser Asn Phe His Asn Phe Lys Leu Asn Ala Pro Ser His His Thr
1760 1765 1770
Leu Arg Pro Leu Gly Leu Ser Ser Thr Ala Trp Tyr Lys Gly Ile
1775 1780 1785
Ser Cys Cys Arg Tyr Leu Glu Arg Leu Lys Leu Pro Gln Gly Asp
1790 1795 1800
His Leu Tyr Ile Ala Glu Gly Ser Gly Ala Ser Met Thr Ile Ile
1805 1810 1815
Glu Tyr Leu Phe Pro Gly Arg Lys Ile Tyr Tyr Asn Ser Leu Phe
1820 1825 1830
Ser Ser Gly Asp Asn Pro Pro Gln Arg Asn Tyr Ala Pro Met Pro
1835 1840 1845
Thr Gln Phe Ile Glu Ser Val Pro Tyr Lys Leu Trp Gln Ala His
1850 1855 1860
Thr Asp Gln Tyr Pro Glu Ile Phe Glu Asp Phe Ile Pro Leu Trp
1865 1870 1875
Asn Gly Asn Ala Ala Met Thr Asp Ile Gly Met Thr Ala Cys Val
1880 1885 1890
Glu Phe Ile Ile Asn Arg Val Gly Pro Arg Thr Cys Ser Leu Val
1895 1900 1905
His Val Asp Leu Glu Ser Ser Ala Ser Leu Asn Gln Gln Cys Leu
1910 1915 1920
Ser Lys Pro Ile Ile Asn Ala Ile Ile Thr Ala Thr Thr Val Leu
1925 1930 1935
Cys Pro His Gly Val Leu Ile Leu Lys Tyr Ser Trp Leu Pro Phe
1940 1945 1950
Thr Arg Phe Ser Thr Leu Ile Thr Phe Leu Trp Cys Tyr Phe Glu
1955 1960 1965
Arg Ile Thr Val Leu Arg Ser Thr Tyr Ser Gly Pro Ala Asn His
1970 1975 1980
Glu Val Tyr Leu Ile Cys Ile Leu Ala Asn Asn Phe Ala Phe Gln
1985 1990 1995
Thr Val Ser Gln Ala Thr Gly Met Ala Met Thr Leu Thr Asp Gln
2000 2005 2010
Gly Phe Thr Leu Ile Ser Pro Glu Arg Ile Asn Gln Tyr Trp Asp
2015 2020 2025
Gly His Leu Lys Gln Glu Arg Ile Val Ala Glu Ala Ile Asp Lys
2030 2035 2040
Val Val Leu Gly Glu Asp Ala Leu Phe Asn Ser Ser Asp Asn Glu
2045 2050 2055
Leu Ile Leu Lys Cys Gly Gly Thr Pro Asn Ala Arg Asn Leu Ile
2060 2065 2070
Asp Ile Glu Pro Val Ala Thr Phe Ile Glu Phe Glu Gln Leu Ile
2075 2080 2085
Cys Thr Met Leu Thr Thr His Leu Lys Glu Ile Ile Asp Ile Thr
2090 2095 2100
Arg Ser Gly Thr Gln Asp Tyr Glu Ser Leu Leu Leu Thr Pro Tyr
2105 2110 2115
Asn Leu Gly Leu Leu Gly Lys Ile Ser Thr Ile Val Arg Leu Leu
2120 2125 2130
Thr Glu Arg Ile Leu Asn His Thr Ile Arg Asn Trp Leu Ile Leu
2135 2140 2145
Pro Pro Ser Leu Arg Met Ile Val Lys Gln Asp Leu Glu Phe Gly
2150 2155 2160
Ile Phe Arg Ile Thr Ser Ile Leu Asn Ser Asp Arg Phe Leu Lys
2165 2170 2175
Leu Ser Pro Asn Arg Lys Tyr Leu Ile Thr Gln Leu Thr Ala Gly
2180 2185 2190
Tyr Ile Arg Lys Leu Ile Glu Gly Asp Cys Asn Ile Asp Leu Thr
2195 2200 2205
Arg Pro Ile Gln Lys Gln Ile Trp Lys Ala Leu Gly Cys Val Val
2210 2215 2220
Tyr Cys His Asp Pro Val Asp Gln Arg Glu Ser Thr Glu Phe Ile
2225 2230 2235
Asp Ile Asn Ile Asn Glu Glu Ile Asp Leu Gly Ile Asp Gly Glu
2240 2245 2250
Glu Ile
2255
<210> 6
<211> 15246
<212> DNA
<213> 人工序列
<400> 6
accaagggga aaatgaagtg gtgactcaaa tcatcaaaga ccctcgagat tacataggtc 60
tggaacttat ggccttcgtg accgacctcg agtcagagta gttcaataag gacctatcaa 120
gtttgggcaa tttttcgtcc ccgacacaaa aatgtcatcc gtgcttaaag catatgagcg 180
attcacactc actcaagaac tgcaagatca gagtgaggaa ggtacaatcc cacctacaac 240
actaaaaccg gtaatcaggg tatttatact aacctctaat aacccagagc taagatcccg 300
gcttcttcta ttctgcctac ggattgttct cagtaatggt gcaagggatt cccatcgctt 360
tggagcatta cttacaatgt tttcgctacc atcagccaca atgctcaatc atgtcaaatt 420
agctgaccag tcaccagaag ctgatatcga aagggtagag atcgatggct ttgaggaggg 480
atcattccgc ttaatcccca atgctcgttc aggtatgagc cgtggagaga tcaatgccta 540
tgctgcactt gcagaagatc tacctgacac actaaaccat gcaacacctt ttgttgattc 600
cgaagtcgag ggaactgcat gggatgagat tgagactttc ttagatatgt gttacagtgt 660
cctaatgcag gcatggatag tgacttgcaa gtgcatgact gcgccagacc aacctgctgc 720
ttctattgag aaacgcctgc aaaaatatcg tcagcaaggc aggatcaacc cgagatatct 780
cctgcaaccg gaggctcgaa gaataatcca gaatgtaatc cgaaagggaa tggtggtcag 840
acatttcctc acctttgaac tgcagcttgc ccgagcacaa agccttgtat caaataggta 900
ttatgctatg gtaggggatg ttggaaagta tatagagaat tgtggaatgg gaggcttctt 960
tttgacacta aaatatgcat taggaaccag atggcccaca cttgctttag ctgcattttc 1020
aggagagcta acaaagctaa agtccctcat ggcattatac cagacccttg gtgagcaggc 1080
ccgatatttg gccctattgg agtcaccaca tttgatggat tttgctgcag caaactaccc 1140
actgctatat agctatgcta tgggaatagg ctatgtgtta gatatcaaca tgaggaacta 1200
cgctttctcc agatcataca tgaataagac atatttccaa ttgggaatgg aaactgcaag 1260
aaaacaacag ggtgcagttg acatgaggat ggcagaagat ctcggtctaa ctcaagccga 1320
acgcaccgag atggcaaata cacttgccaa attgaccaca gcaaatcgag gggcagacac 1380
caggggagga gtcaacccgt tctcatctat cactgggaca actcaggtgc ccgctgcagc 1440
aacaggtgac acattcgaga gttacatggc agcggatcga ctgaggcaga gatatgctga 1500
tgcaggcacc cacgatgatg agatgccacc attggaagag gaggaagagg acgacacatc 1560
tgcaggtcca cgcactggac taactcttga acaagtggcc ttggacatcc agaacgcagc 1620
agttggagct cccatccata cagatgacct gaatgccgca ctgggtgatc ttgacatcta 1680
gacaattcag atcccaatct taaatcgaca cacctaattg accagttaga tggaactaca 1740
gtggattcca tgaggttcct gcctaccatc ggcttttaag aaaaaaatag gcccggacgg 1800
gttagcaaca agcgaccgcc gatgccaata acacaatcca caatctacaa tggatcccac 1860
tgatctgagc ttctccccag atgagatcaa taagctcata gagacaggcc tgaatactgt 1920
ggagtattta acttcccaac aagtcacagg aacatcctct cttggaaaga atacaatacc 1980
accaggggtc acaggactac caaccaatgc tgcagaggca aagatccaag agtcaaccaa 2040
ccatcagaag ggttcagttg gtgggggcgc aaaaccaaag aaaccgcgac caaaaattgc 2100
cattgtgcca gcagatgaca aaacggtgcc cggaaagccg atcccaaacc ctctattagg 2160
tctggactcc accccgagca cccaaactgt gcttgatcta agtgggaaaa cattaccatc 2220
aggatcctat aagggggtta aacttgcgaa ctttggaaaa gaaaatctga tgacacggtt 2280
catcgaggaa cccagagaga atcctatcgc aaccaattcc cccatcgatt ttaagagggg 2340
cagggatacc ggcgggttcc atagaaggga gtactcaatc ggatgggtgg gagatgaagt 2400
caaggtcact gagtggtgca atccatcctg ttctccaatc accgctgcag caaggcgatt 2460
tgaatgcact tgtcaccagt gtccagtcac ttgctctgaa tgtgaacgag atacttaata 2520
cagtgagaaa tttggactct cggatgaatc aactggagac aaaagtagat cgcattctct 2580
catctcagtc tctaatccag accatcaaga atgacatagt tggacttaaa gcagggatgg 2640
ctactttaga aggaatgatt acaactgtga aaatcatgga tccgggagtt cccagtaata 2700
ttactgtgga agatgtacgc aagaaactaa gtaaccatgc tgttgttgtg ccagaatcat 2760
tcaatgatag tttcttgact caatctgaag atgtaatttc acttgatgag ttggctcgac 2820
caactgcaac aagtgttaag aagattgtca ggaaggttcc tcctcagaag gatctgactg 2880
gattgaagat cacactagag caattggcaa aggattgcat cagcaaaccg aagatgaggg 2940
aagagtatct cctcaaaatc aaccaggctt ccagtgaggc tcagctaatt gacctcaaga 3000
aagcaatcat ccgcagtgca atttgatcaa gaaacaccca attacactac actggtatga 3060
cactgtacta accctgaggg ttttagaaaa aacgattaac gataaataag cccgaacact 3120
acacaccacc cgaggcagcc atgccatcca tcagcatccc cgcagacccc accaatccac 3180
gtcaatcaat aaaagcgttc ccaattgtga tcaaccgtga tgggggtgag aaaggtcgct 3240
tggttaaaca actacgcaca acctacttga atgacctaga tactcatgag ccactggtga 3300
cattcgtaaa tacttatgga ttcatctacg aacaggatcg gggaaatacc attgtcggag 3360
aggatcaaca tgggaagaaa agagaggctg tgactgctgc aatggttacc cttggatgtg 3420
ggcctaatct accatcatta gggaatgtcc tgggacaact gagtgaattc caggtcattg 3480
ttaggaagac atccagcaaa gcggaagaga tggtctttga aattgttaag tatccgagaa 3540
tatttcgggg tcatacatta atccagaaag gactagtctg tgtctccgca gaaaaatttg 3600
ttaagtcacc agggaaagta caatctggaa tggactatct cttcattccg acatttctgt 3660
cagtgactta ctgtccagct gcaatcaaat ttcaggtact tggccccatg ttgaaaatga 3720
gatcaagata cactcagagc ttacaacttg aactaatgat aagaatcctg tgtaagcccg 3780
attcgccact tatgaaggtc catatccctg acaaggaagg aagaggatgt cttgtatcag 3840
tatggttgca tgtatgcaat atcttcaaat caggaaacaa gaatggcagt gagtggcagg 3900
aatactggat gagaaagtgt gctaacatgc aacttgaagt gtcgattgca gatatgtggg 3960
gaccaactat cataattcat gccagaggtc acattcccaa aagtgctaag ttgttttttg 4020
gaaagggtgg atggagctgc catccacttc acgaagttgt tccaagtgtc actaagacac 4080
tatggtccgt gggctgtgag attacaaagg cgaaggcaat aatacaagag agtagcatct 4140
ctcttctcgt ggagactact gacatcataa gtccaaaagt caaaatttca tctaagcatc 4200
gccgctttgg gaaatcaaat tggggtctgt tcaagaaaac caaatcactg cccaacctga 4260
cggcgctgga atgactgacc cccaatcgag actacaccac ctcaaactat aggtgggtgg 4320
tacctcagtg attaatctcg taagcactga tcgtaggcta caacacacta atattatcca 4380
gattagagag cttaattagc tctgtattaa taataacact actattccaa taactggaat 4440
caccagcttg atttatctcc aaaatgattc aaagaaaaca aatcatatta agactatcct 4500
aagcacgaac ccatatcgtc cttcaaatca tgggtactat aattcaattt ctggtggtct 4560
cctgtctatt ggcaggagca ggcagtcttg atccagcagc cctcatgcaa atcggtgtca 4620
ttccaacaaa tgtccggcaa cttatgtatt atactgaggc ctcatcagca ttcattgttg 4680
tgaagttaat gcctacaatt gactcgccga ttagtggatg taatataaca tcaatttcaa 4740
gctataatgc aacagtgaca aaactcctac agccgatcgg tgagaatttg gagacgatta 4800
ggaaccagtt gattccaact cggaggagac gccggtttgc aggggtggtg attggattag 4860
ctgcattagg agtagctact gccgcacagg tcactgccgc agtagcacta gtaaaggcaa 4920
atgaaaatgc tgcggctata ctcaatctca aaaatgcaat ccaaaaaaca aatgcagcag 4980
ttgcagatgt ggtccaggcc acacaatcac taggaacggc agttcaagca gttcaagatc 5040
acataaacag tgtggtaagt ccagcaatta cagcagccaa ttgtaaagcc caagatgcta 5100
tcattggctc aatcctcaat ctctatttga ccgagttgac aactatcttc cacaatcaaa 5160
ttacaaaccc tgcattgagt cctattacaa ttcaagcttt aaggatccta ctagggagta 5220
ccttgccgac tgtggtcgaa aaatctttca atacccagat aagtgcggct gagcttctct 5280
catcagggtt attgacaggc cagattgtgg gattagattt gacctatatg cagatggtca 5340
taaaaattga gctgccaact ttagctgtac aacctgcaac ccagatcata gatctggcca 5400
ccatttctgc attcattaac aatcaagaag tcatggccca attaccaaca cgtgttattg 5460
tgactggcag cttgatccaa gcctatcccg catcgcaatg cactattaca cccaacactg 5520
tgtactgtag gtataatgat gcccgagtac tctcagatga tacgatggct tgcctccaag 5580
gtaacttgac aagatgcacc ttctctccag tggttgggag ctttctcact cgattcgtgc 5640
tgttcgatgg aatagtttat gcaaattgca ggtcgatgtt gtgcaagtgc atgcagcctg 5700
ctgctgtgat cctacagccg agttcatccc ctgtaactgt cattgacatg tacaaatgtg 5760
tgagtctgca gcttgacaat ctcagattca ccatcactca attggccaat gtaacctaca 5820
atagcaccat caagcttgaa acatcccaga tcttgcctat tgctccgttg gatatatccc 5880
agaatctagc tgcggtgaat aagagtctaa gtgatgcact acaacactta gcacaaagtg 5940
acacatacct ttctgcaatc acatcagcta cgactacaag tgtattatcc ataatagcaa 6000
tctgtcttgg atcgttaggt ttaatattaa taatcttgct cagtgtagtt gtgtggaagt 6060
tattgaccat tgtcgctgct aatcgaaata gaatggagaa ttttgtttat cataattcag 6120
cattccacca ctcacgatct gatctcagtg agaaaaatca acctgcaact cttggaacaa 6180
gataagacag taatccatta gtaattttta agaaaaaaac gataggaccg aaactagtat 6240
tgaaagaacc gtctcggtca atctaggtaa tcgagctgat accgtctcgg aaagctcaaa 6300
tcatgctgcc tgatccggaa gatccggaaa gcaaaaaagc tacaaggaga acaggaaacc 6360
taattatctg cttcctattc atcttctttc cgtttgtaaa cttcattgtt ccaactctaa 6420
gacacttgct gtcctaacac ctgctatagg ctatccactg catcatctct cctgccatac 6480
ttcctactca catcatatct attttaaaga aaaaagaggc ccgaacacta atcgtgccgg 6540
cagtgccact gcacacacaa cactacacat acaatacact acaatggttg cagaagatgc 6600
ccctgttagg ggcacttgcc gagtattatt tcgaacaaca actttaattt ttctatgcac 6660
actattagca ttaagcatct ctatccttta tgagagttta ataacccaaa agcaaatcat 6720
gagccaagca ggctcaactg gatctaattc tagattagga agtatcactg atcttcttaa 6780
taatattctc tctgtcgcaa atcagattat atataactct gcagtcgctc tacctctaca 6840
attggacact cttgaatcaa cactccttac agccattaag tctcttcaaa caagtgacaa 6900
gctagaacag aactgctcgt ggggtgctgc actgattaat gataatagat acattaatgg 6960
catcaatcag ttctatttct caattgctga gggtcgcaag ctgacacttg gcccacttct 7020
taatatacct agtttcattc caactgccac gacaccagag ggctgcacca ggatcccatc 7080
attctcgctc accaagacac actggtgtta tacacacaat gttatcctga atggatgcca 7140
ggatcatgta tcctcaaatc aatttgtttc catgggaatc attgaaccca cttctgccgg 7200
gtttccatcc cttcgaaccc taaagactct atatctcagc gatggggtca atcgtaagag 7260
ctgctctatc agtacagttc cggggggttg tatgatgtac tgtttcgtct ctactcaacc 7320
agagagggat gactactttt ctaccgctcc tccagaacaa cgaattatta taatgtacta 7380
taatgataca atcgtagagc gcataattaa tccacccggg gtactagatg tatgggcaac 7440
attgacccca ggaacaggaa gcggggtata ttatttaggt tgggtactct ttccaatata 7500
tggcggcgtg attaaagata cgagtttatg gaataatcaa gcaaataaat actttatccc 7560
ccagatggtt gctgctctct gctcacaaaa ccaggcaact caagtccaaa atgctaagtc 7620
atcatactat agcagctggt ttggcaatcg aatgattcag tctgggatcc tggcatgtcc 7680
tcttcaacag gatctaacca atgagtgttt agttctgccc ttttctaatg atcaggtgct 7740
tatgggtgct gaagggagat tatacatgta tggtgactcg gtgtattact accaaagaag 7800
caatagttgg tggcctatga ccatgctgta taaggtaacc ataacattca ctaatggtca 7860
gccatctgct atatcagctc agaatgtgcc cacacagcag gtccctagac ctgggacagg 7920
aagctgctct gcaacaaata gatgtcccgg tttttgcttg aaaggagtgt atgctgatgc 7980
ctggttactg accaaccctt cgtctaccag tacatttgga tcagaagcaa ccttcactgg 8040
ttcttatctc aacgcagcaa ctcagcgtat caatccgacg atgtatatcg cgaacaacac 8100
acagatcata agctcacagc aatttggatc aagcggtcaa gaagcagcat atggccacac 8160
aacttgtttt agggacacag gctctgttat ggtatactgt atctatatta ttgaattgtc 8220
ctcatctctc ttaggacaat ttcagattgt cccatttatc cgtcaggtga cactatccta 8280
aaggcagaag catccaggtc tgacccagcc aatcaaagca ttataccaga ccatggaatg 8340
cataccaaac attattgaca ctaatgacac acaaaattgg ttttaagaaa aaccaagaga 8400
acaataggcc agaatggctg ggtctcggga gatattactc cctgaagtcc atctcaattc 8460
accaattgta aagcataagc tatactatta cattctactt ggaaacctcc caaatgagat 8520
cgacattgac gatttaggtc cattacataa tcaaaattgg aatcaaatag cacatgaaga 8580
gtctaactta gcccaacgct tggtaaatgt aagaaatttt ctaattaccc acatctctga 8640
tcttagaaag ggccattggc aagagtatgt caatgtaata ctgtggccgc gaattcttcc 8700
cttgatcccg gattttaaaa tcaatgacca attgcctcta ctcaaaaatt gggacaagtt 8760
agttaaagaa tcatgttcag taatcaatgc gggtacttcc cagtgcattc agaatctcag 8820
ctatggactg acaggtcgtg ggaacctctt tacacgatca cgtgaactct ctggtgaccg 8880
cagggatatt gatcttaaga cggttgtggc agcatggcat gactcagact ggaaaagaat 8940
aagtgatttt tggattatga tcaaattcca gatgagacaa ttaattgtta ggcaaacaga 9000
tcataatgat cctgatttaa tcacgtatat cgaaaataga gaaggcataa tcatcataac 9060
ccctgaactg gtagcattat ttaacactga gaatcataca ctaacataca tgacctttga 9120
aattgtactg atggtttcag atatgtacga aggtcgtcac aacattttat cactatgcac 9180
agttagcact tacctgaatc ctctgaagaa aagaataaaa tatttattga gccttgtaga 9240
taacttagct tttcagatag gtgatgctgt atataacata attgctttgc tagaatcctt 9300
tgtatatgca cagttgcaaa tgtcagatcc catcccagaa ctcagaggac aattccatgc 9360
attcgtatgt tctgagattc ttgatgcact aaggggaact aatagtttca cccaggatga 9420
atcaagaact gtgacaacca atttgatatc cccattccaa gatctgaccc cagatcttac 9480
ggctgaattg ctctgtataa tgaggctttg gggacacccc atgctcaccg ccagtcaagc 9540
tgcgggaaag gtacgcgagt ccatgtgtgc tggaaaagta ttagactttc ccaccattat 9600
gaaaacacta gcctttttcc atactattct gatcaatgga tacaggagga agcatcatgg 9660
agtatggcca cccttaaact taccgggtaa tgcttcaaag ggtctcacgg aacttatgaa 9720
tgacaatact gagataagct atgaattcac acttaagcat tggaaggaaa tctctcttat 9780
aaaattcaag aaatgttttg atgcagacgc aggtgaggaa ctcagtatat ttatgaaaga 9840
taaagcaatt agtgccccaa aacaagattg gatgagtgtg tttagaagaa gcctaatcaa 9900
acagcgccat cagcatcatc aggtccccct accaaatcca ttcaatcgac ggctattgct 9960
aaactttctc ggagatgaca aattcgaccc gaatgtggag ctacagtatg taacatcagg 10020
tgagtatcta catgatgaca cgttttgtgc atcatattca ctaaaagaga aggaaattaa 10080
acctgatggt cgaatttttg caaagttgac taagagaatg agatcatgtc aagttatagc 10140
agaatctctt ttagcgaacc atgctgggaa gttaatgaaa gagaatggtg ttgtgatgaa 10200
tcagctatca ttaacaaaat cactattaac aatgagtcag attggaataa tatccgagaa 10260
agctagaaaa tcgactcgag ataacataaa tcaacctggt ttccagaata tccagagaaa 10320
taaatcacat cactccaagc aagtcaatca gcgagatcca agtgatgact ttgaattggc 10380
agcatctttt ttaactactg atctcaaaaa atattgttta caatggaggt accagacaat 10440
tatcccattt gctcaatcat taaacagaat gtatggttat cctcatctct ttgagtggat 10500
tcacttacgg ctaatgcgta gtacacttta cgtgggggat cccttcaacc caccagcaga 10560
taccagtcaa tttgatctag ataaagtaat taatggagat atcttcattg tatcacccag 10620
aggtggaatt gaagggctat gtcaaaaggc ttggacaatg atatctatct ctgtgataat 10680
tctatctgcc acagagtctg gcacacgagt aatgagtatg gtgcagggag ataatcaagc 10740
aattgctgtc accacacgag taccaaggag cctgccgact cttgagaaaa agactattgc 10800
ttttagatct tgtaatctat tctttgagag gttaaaatgt aataattttg gattaggtca 10860
ccatttgaaa gaacaagaga ctatcattag ttctcacttc tttgtttata gcaagagaat 10920
attctatcag gggaggattc taacgcaagc cttaaaaaat gctagtaagc tctgcttgac 10980
agctgatgtc ctaggagaat gtacccaatc atcatgttct aatcttgcaa ctactgtcat 11040
gaggttaact gagaatggtg ttgaaaaaga tatctgtttc tacttgaata tctatatgac 11100
catcaaacag ctctcctatg atatcatctt ccctcaagtg tcaattcctg gagatcagat 11160
cacattagaa tacataaata atccacacct ggtatcacga ttggctcttc tgccatccca 11220
gctaggaggt ctaaactacc tgtcatgcag taggctgttc aatcgaaaca taggagaccc 11280
ggtggtttcc gcagttgcag atcttaagag attaattaaa tcaggatgta tggattactg 11340
gatcctttat aacttattag ggagaaaacc gggaaacggc tcatgggcta ctttagcagc 11400
tgacccgtac tcaatcaata tagagtatca atacccccca actacagctc ttaagaggca 11460
cacccaacaa gctctgatgg aactcagtac gaatccaatg ttacgtggca tattctctga 11520
caatgcacag gcagaagaaa ataatcttgc tagatttctc ctggataggg aggtgatctt 11580
tccgcgtgta gctcacatca tcattgagca aaccagtgtc gggaggagaa aacagattca 11640
aggatatttg gattcaacta gatcaataat gagtaaatca ctagaaatta agcccttgtc 11700
caataggaag cttaatgaaa tactggatta caacatcaat tacctagctt acaatttggc 11760
attactcaag aatgctattg aacctccgac ttatttgaaa gcaatgactc ttgaaacatg 11820
tagcatcgac attgcaagga gcctccggaa gctctcctgg gccccactct tgggtgggag 11880
aaatcttgaa gggttagaga cgccagatcc cattgaaatt actgcaggag cattaattgt 11940
tggatcgggc tactgtgaac agtgtgctgc aggagacaat cgattcacat ggtttttctt 12000
gccatctggt atcgagatag gaggggatcc ccgtgataat cctcctatcc gtgtaccgta 12060
cattggctcc aggactgatg agaggagggt agcctcaatg gcatacatca ggggtgcctc 12120
gagtagccta aaagcagttc ttagactggc gggagtgtac atctgggcat tcggagatac 12180
tctggagaat tggatagatg cactggattt gtctcacact agagttaaca tcacacttga 12240
acagctgcaa tccctcaccc cacttccaac ctctgccaat ctaacccatc ggttggatga 12300
tggcacaact accctaaagt ttactcctgc gagctcttac accttttcaa gtttcactca 12360
tatatcaaat gatgagcaat acctgacaat taatgacaaa actgcagatt caaatataat 12420
ctaccaacag ttaatgatca ctggactcgg aattttagaa acatggaata atcccccaat 12480
caatagaaca ttcgaagaat ctaccctaca tttgcacact ggtgcatcat gttgtgtccg 12540
acctgtggac tcctgcatca tctcagaagc attaacagtc aagccacata ttacagtacc 12600
gtacagcaat aaatttgtat ttgatgaaga cccgctatct gaatatgaga ctgcaaaact 12660
ggaatcgtta tcatttcaag cccaattagg caacattgat gctgtagata tgacaggtaa 12720
attaacatta ttgtcccaat tcactgcaag gcagattatt aatgcaatca ctggactcga 12780
tgagtctgtc tctcttacta atgatgccat tgttgcatca gactatgtct ccaattggat 12840
tagtgaatgc atgtatacca aattagatga attatttatg tattgtgggt gggaactact 12900
attggaacta tcctatcaaa tgtattatct gagggtagtt gggtggagta atatagtgga 12960
ttattcttac atgatcttga gaagaatccc gggtgcagca ttaaacaatc tggcatctac 13020
attaagtcat ccaaaacttt tccgacgagc tatcaaccta gatatagttg cccccttaaa 13080
tgctcctcat tttgcatctc tggactacat caagatgagt gtggatgcaa tactctgggg 13140
ctgtaaaaga gtcatcaatg tgatctccaa tggaggggac ttagaattag ttgtgacatc 13200
tgaagatagc cttattctca gtgaccgatc catgaatctc attgcaagga aattaacttt 13260
attatcactg attcaccata atggtttgga actaccaaag attaaggggt tctctcctga 13320
tgagaagtgt ttcgctttga cagaattttt gaggaaagtg gtgaactcag ggttgagttc 13380
aatagagaac ctatcaaatt ttatgtacaa tgtggagaac ccacggcttg cagcattcgc 13440
cagcaacaat tactacctga ccagaaaatt attgaattca atacgagata ctgagtcggg 13500
tcaagtagca gtcacctcat attatgaatc attagaatat attgatagtc ttaagctaac 13560
cccacatgtg cctggtacct catgcattga ggatgatagt ctatgtacaa atgattacat 13620
aatctggatc atagagtcta atgcaaactt ggagaagtat ccaattccaa atagccctga 13680
ggatgattcc aatttccata actttaagtt gaatgctcca tcgcaccata ccttacgccc 13740
attagggttg tcatcaactg cttggtataa gggtataagc tgttgcaggt accttgagcg 13800
attaaagcta ccacaaggtg atcatttata tattgcagaa ggtagtggtg ccagtatgac 13860
aatcatagaa tacctattcc caggaagaaa gatatattac aattctttat ttagtagtgg 13920
tgacaatccc ccacaaagaa attatgcacc aatgcctact cagttcattg agagtgtccc 13980
atacaagctc tggcaagcac acacagatca atatcccgag atttttgagg acttcatccc 14040
tctatggaac ggaaatgccg ccatgactga cataggaatg acagcttgtg tagaattcat 14100
catcaatcga gtcggcccaa ggacttgcag tttagtacat gtagatttgg aatcaagtgc 14160
aagcttaaat caacaatgcc tgtcaaagcc gataattaat gctatcatca ctgctacaac 14220
tgttttgtgc cctcatgggg tgcttattct gaaatatagt tggttgccat ttactagatt 14280
tagtactttg atcactttct tatggtgcta ctttgagaga atcactgttc ttaggagcac 14340
atattctggt ccagctaatc atgaggttta tttaatttgt atccttgcca acaactttgc 14400
attccagact gtctcgcagg caacaggaat ggcgatgact ttaaccgatc aagggtttac 14460
tttgatatca cctgaaagaa taaatcagta ttgggatggt cacttgaagc aagaacgtat 14520
cgtagcagaa gcaattgata aggtggttct aggagaagat gctctattca attcgagtga 14580
taatgaatta attctcaaat gtggagggac accaaatgca cggaatctta tcgatatcga 14640
gccagtcgca actttcatag aatttgaaca actgatctgc acaatgttaa caacccactt 14700
gaaggaaata attgatataa caaggtctgg aacccaggat tatgaaagtt tattactcac 14760
tccttacaat ttaggtcttc ttggtaaaat cagtacgata gtgagattat taacagaaag 14820
gattctaaat catactatca ggaattggtt gatcctccca ccttcgctcc ggatgatcgt 14880
gaagcaggac ttggaattcg gcatattcag gattacttcc atcctcaatt ctgatcggtt 14940
cctgaagctt tctccaaata ggaaatactt gattacacaa ttaactgcag gctacattag 15000
gaaattgatt gagggggatt gtaatatcga tctaaccagg cctatccaaa aacaaatctg 15060
gaaagcatta ggttgtgtag tctattgtca cgatccagta gatcaaaggg aatcaacaga 15120
gtttattgat ataaatatta atgaagaaat agacctcggg atcgatggcg aggaaatcta 15180
aatatatcaa gaatcagaat tagtttaaga aaaaagaagt ggattaatct tggttttccc 15240
cttggt 15246
<210> 7
<211> 28
<212> DNA
<213> 人工序列
<400> 7
aggtcgatgt tgtgcaagtg catgcagc 28
<210> 8
<211> 37
<212> DNA
<213> 人工序列
<400> 8
ggtggtttaa acagatttga gctttccgag acggtag 37
<210> 9
<211> 40
<212> DNA
<213> 人工序列
<400> 9
aaatctgttt aaaccacctg ctataggcta tccactgcat 40
<210> 10
<211> 23
<212> DNA
<213> 人工序列
<400> 10
agtgtcagct tgcgaccctc agc 23
<210> 11
<211> 26
<212> DNA
<213> 人工序列
<400> 11
caactcttgg aacaagataa gacagt 26
<210> 12
<211> 24
<212> DNA
<213> 人工序列
<400> 12
catcttctgc aaccattgta gtgt 24

Claims (10)

1.一种表达冠状病毒Spike蛋白的受体结合域串联二聚体的重组副流感病毒5型载体,其特征在于,所述重组副流感病毒5型载体包含一种副流感病毒5型基因组,所述副流感病毒5型基因组包含冠状病毒Spike蛋白的受体结合域串联二聚体的基因序列。
2.根据权利要求1所述的表达冠状病毒Spike蛋白的受体结合域串联二聚体的重组副流感病毒5型载体,其特征在于,所述副流感病毒5型基因组为:用序列甲替换一种副流感病毒5型基因组的小疏水蛋白基因核苷酸序列,所得;
所述序列甲为如下1)或2)或3):
A)SEQ ID NO:1所示DNA分子;
B)在严格条件下与A)限定的DNA分子杂交且编码所述冠状病毒Spike蛋白的受体结合域串联二聚体的DNA序列;
C)与A)或B)限定的DNA序列具有99%以上、95%以上、90%以上、85%以上或者80%以上同一性且编码所述冠状病毒Spike蛋白的受体结合域串联二聚体的DNA序列。
3.一种组合物,其特征在于,包括重组副流感病毒5型载体、表达辅助蛋白的辅助重组质粒—NP、辅助重组质粒—P和辅助重组质粒—L;所述表达辅助蛋白的辅助重组质粒—NP、辅助重组质粒—P和辅助重组质粒—L是将副流感病毒5型的NP、P和L蛋白的编码基因分别***哺乳动物表达载体中,得到辅助重组质粒—NP、辅助重组质粒—P和辅助重组质粒—L。
4.一种在细胞中表达冠状病毒Spike蛋白的受体结合域串联二聚体的方法,其特征在于,该方法包括使该细胞与如权利要求1或2中所述的表达冠状病毒Spike蛋白的受体结合域串联二聚体的重组副流感病毒5型载体相接触。
5.一种表达冠状病毒Spike蛋白的受体结合域串联二聚体的重组副流感病毒5型载体的制备方法,其特征在于,包括如下步骤:
1)将副流感病毒5型全基因组反转录得到的cDNA***克隆载体中,得到重组质粒pPIV5;
2)用序列甲替换步骤1)中重组质粒pPIV5中副流感病毒5型的小疏水蛋白基因核苷酸序列;所述序列乙为如下1)或2)或3):
A)SEQ ID NO:1所示DNA分子;
B)在严格条件下与A)限定的DNA分子杂交且编码所述冠状病毒Spike蛋白的受体结合域串联二聚体的DNA序列;
C)与A)或B)限定的DNA序列具有99%以上、95%以上、90%以上、85%以上或者80%以上同一性且编码所述冠状病毒Spike蛋白的受体结合域串联二聚体的DNA序列。
6.根据权利要求5所述的方法,其特征在于,步骤1)中所述克隆载体为带有T7 RNA聚合酶启动子序列、带有丁肝核酶序列、T7 RNA聚合酶转录终止序列的克隆载体。
7.一种新型冠状病毒(2019-nCoV)疫苗的制备方法,其特征在于,所述疫苗的制备方法包括如下步骤:将权利要求1或2所述表达冠状病毒Spike蛋白的受体结合域串联二聚体的重组副流感病毒5型载体、表达辅助蛋白的辅助重组质粒—NP、辅助重组质粒—P和辅助重组质粒—L共转染宿主细胞;所述表达辅助蛋白的辅助重组质粒—NP、辅助重组质粒—P和辅助重组质粒—L是将副流感病毒5型的NP、P和L蛋白的编码基因分别***哺乳动物表达载体中,得到辅助重组质粒—NP、辅助重组质粒—P和辅助重组质粒—L。
8.根据权利要求7所述的制备方法,其特征在于,所述宿主细胞为BSR-T7细胞,MDBK细胞,Vero细胞或BHK-21细胞。
9.权利要求7或8所述方法制备得到的疫苗。
10.权利要求1或2所述重组副流感病毒5型载体或权利要求5或6所述方法制备的重组副流感病毒5型载体在如下任一一种中的应用:
(1)制备提高动物体内针对冠状病毒2019-nCoV Spike蛋白抗体水平的产品中的应用;
(2)制备预防或辅助预防冠状病毒2019-nCoV引起的疾病产品中的应用。
CN202110327109.6A 2021-03-26 2021-03-26 一种表达冠状病毒受体结合域串联二聚体的重组副流感病毒5型载体 Pending CN113005149A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110327109.6A CN113005149A (zh) 2021-03-26 2021-03-26 一种表达冠状病毒受体结合域串联二聚体的重组副流感病毒5型载体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110327109.6A CN113005149A (zh) 2021-03-26 2021-03-26 一种表达冠状病毒受体结合域串联二聚体的重组副流感病毒5型载体

Publications (1)

Publication Number Publication Date
CN113005149A true CN113005149A (zh) 2021-06-22

Family

ID=76407873

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110327109.6A Pending CN113005149A (zh) 2021-03-26 2021-03-26 一种表达冠状病毒受体结合域串联二聚体的重组副流感病毒5型载体

Country Status (1)

Country Link
CN (1) CN113005149A (zh)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104093422A (zh) * 2012-01-24 2014-10-08 乔治亚大学研究基金公司 基于副流感病毒5的疫苗
US20180044644A1 (en) * 2015-04-28 2018-02-15 University Of Georgia Research Foundation, Inc. PIV5-Based Amplifying Virus-Like Particles
WO2022061264A1 (en) * 2020-09-21 2022-03-24 University Of Georgia Research Foundation, Inc. Piv5-based covid-19 vaccine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104093422A (zh) * 2012-01-24 2014-10-08 乔治亚大学研究基金公司 基于副流感病毒5的疫苗
US20180044644A1 (en) * 2015-04-28 2018-02-15 University Of Georgia Research Foundation, Inc. PIV5-Based Amplifying Virus-Like Particles
WO2022061264A1 (en) * 2020-09-21 2022-03-24 University Of Georgia Research Foundation, Inc. Piv5-based covid-19 vaccine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LI K.等: "Single-Dose, Intranasal Immunization with Recombinant Parainfluenza Virus 5 Expressing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Spike Protein Protects Mice from Fatal MERS-CoV Infection", 《MBIO》, 30 April 2020 (2020-04-30), pages 2 *
XU, K.等: "Recombinant chimpanzee adenovirus AdC7 expressing dimeric tandem-repeat RBD of SARS-CoV-2 spike protein protects mice against COVID-19", 《BIORXIV》, 8 February 2021 (2021-02-08), pages 11 - 12 *
高菽蔓等: "副流感病毒5型CC-14株辅助质粒的构建及鉴定", 《中国生物制品学杂志》, no. 06, 20 June 2016 (2016-06-20) *

Similar Documents

Publication Publication Date Title
Krishnamurthy et al. Recovery of a virulent strain of Newcastle disease virus from cloned cDNA: expression of a foreign gene results in growth retardation and attenuation
KR0179994B1 (ko) 칠면조의 재조합 포진바이러스 및 이로부터 유도된 생존상태의 벡터 백신
CN111575247B (zh) 一种新城疫嵌合病毒标记疫苗株及其构建方法和应用
CN104962581B (zh) 一种表达非洲猪瘟病毒p72蛋白的重组病毒疫苗株
CN112011521A (zh) 一种重组新城疫病毒载体新型冠状病毒疫苗候选株及其构建方法和应用
CN113073116B (zh) 一种表达新冠病毒Spike蛋白重组副流感病毒5型制备和应用
JP2009529861A (ja) 鳥インフルエンザウイルスのh5ヘマグルチニンを発現する組み換えニューキャッスル病ウイルス
CN107227311B (zh) 重组猪细小病毒样粒子及其制备方法和应用
CN109321534A (zh) 一种重组基因viii型新城疫病毒弱毒株
CN103224914A (zh) 表达融合外源表位n蛋白的重组小反刍兽疫病毒的构建及应用
CN104195116B (zh) 一种表达鹅细小病毒vp3基因的重组新城疫病毒及其构建方法
CN109321535A (zh) 一种热稳定的新城疫病毒弱毒疫苗候选株
CN110452889B (zh) 一种表达bvdv-e0的重组牛肠道病毒的构建方法与初步应用
CN102458427B (zh) 麻疹-疟疾联合疫苗
CN113913461A (zh) 牛病毒性腹泻e0-e2基因重组腺病毒疫苗构建方法
JP2022050586A (ja) パラミクソウイルスおよび使用方法
CN114524862A (zh) 禽流感(h5+h7)三价dna疫苗的构建及其应用
CN112111503B (zh) 同时预防禽流感h5和h9亚型的腺病毒载体二价苗及其制备方法
JP4691495B2 (ja) コロナウイルススパイクs1融合蛋白及びその発現ベクター
Iwasaki et al. Characterization of Oita virus 296/1972 of Rhabdoviridae isolated from a horseshoe bat bearing characteristics of both lyssavirus and vesiculovirus
CN116144612B (zh) 重组乙型流感病毒及其制备方法与应用
CN113005149A (zh) 一种表达冠状病毒受体结合域串联二聚体的重组副流感病毒5型载体
CN109136200B (zh) 一种重组传染性造血器官坏死病毒及其构建方法与应用
CN112029735B (zh) 一种***病毒非结构蛋白3b优势表位缺失标记毒株及其制备方法和应用
CN109295095A (zh) 一种热稳定的基因viii型新城疫弱毒株外源基因表达载体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20210622